Education
About Us
Working with TipRanks
Follow Us
Bruker Corp (BRKR)
NASDAQ:BRKR
BRKR Stock Chart & Stats
$40.11
-$0.59(-0.96%)
At close: 4:00 PM EST
$40.11
-$0.59(-0.96%)
Day’s Range― - ―
52-Week Range$28.53 - $56.22
Previous CloseN/A
Volume340.61K
Average Volume (3M)2.38M
Market Cap
$6.09B
Enterprise Value$7.66B
Total Cash (Recent Filing)$298.80M
Total Debt (Recent Filing)$1.87B
Price to Earnings (P/E)―
Beta1.16
Next Earnings
May 06, 2026EPS Estimate
0.23Next Dividend Ex-DateN/A
Dividend Yield0.42%
Share Statistics
EPS (TTM)0.59
Shares Outstanding151,941,150
10 Day Avg. Volume2,286,700
30 Day Avg. Volume2,377,650
Financial Highlights & Ratios
PEG Ratio6.94
Price to Book (P/B)2.89
Price to Sales (P/S)2.08
P/FCF Ratio165.16
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue2.23
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda24.26
Forecast
1Y Price Target
$47.92Price Target Upside19.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)2.12
Revenue Forecast (FY)$3.57B
Bulls Say, Bears Say
Bulls Say
Analyst SentimentAnalysts maintain Buy ratings and a constructive view with more conservative valuation assumptions, signaling continued confidence in the company's longer-term opportunity relative to peers.
Cost Reduction And Margin OutlookA broad cost-reduction program and recent expense actions are expected to materially improve margins and support an earnings recovery if management executes as planned.
End-market Demand And Product StrengthGrowing demand outside the United States in lab automation, spatial biology and pharmaceutical instrument spending, combined with product innovation, supports revenue and bookings momentum.
Bears Say
Academic And Government Demand WeaknessChoppy demand from academic and government customers and cautious commentary about that market lower visibility and could weigh on bookings and near-term results.
Guidance And Seasonality UncertaintyGuidance that implies a steep ramp and unusually skewed seasonality increases uncertainty around the timing of revenue and profit improvements and heightens execution risk.
Margin Shortfall And Execution RiskA reported gross margin shortfall attributed to adverse sales mix, tariffs and currency effects raises doubts about near-term profitability and the ability to hit margin targets.
Bruker News
BRKR FAQ
What was Bruker Corp’s price range in the past 12 months?
Bruker Corp lowest stock price was $28.53 and its highest was $56.22 in the past 12 months.
What is Bruker Corp’s market cap?
Bruker Corp’s market cap is $6.09B.
When is Bruker Corp’s upcoming earnings report date?
Bruker Corp’s upcoming earnings report date is May 06, 2026 which is in 65 days.
How were Bruker Corp’s earnings last quarter?
Bruker Corp released its earnings results on Feb 12, 2026. The company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by -$0.06.
Is Bruker Corp overvalued?
According to Wall Street analysts Bruker Corp’s price is currently Undervalued.
Does Bruker Corp pay dividends?
Bruker Corp pays a Quarterly dividend of $0.05 which represents an annual dividend yield of 0.42%. See more information on Bruker Corp dividends here
What is Bruker Corp’s EPS estimate?
Bruker Corp’s EPS estimate is 0.23.
How many shares outstanding does Bruker Corp have?
Bruker Corp has 151,941,150 shares outstanding.
What happened to Bruker Corp’s price movement after its last earnings report?
Bruker Corp reported an EPS of $0.59 in its last earnings report, missing expectations of $0.65. Following the earnings report the stock price went down -11.596%.
Which hedge fund is a major shareholder of Bruker Corp?
Currently, no hedge funds are holding shares in BRKR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bruker Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.92 (19.47% Upside)
$47.92 (19.47% Upside)
Blogger Sentiment
Neutral
BRKR Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $243.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.59%
12-Months-Change
Fundamentals
Return on Equity
-0.40%
Trailing 12-Months
Asset Growth
7.49%
Trailing 12-Months
Company Description
Bruker Corp
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
BRKR Company Deck
BRKR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced/Neutral: The company showed meaningful positives including a Q4 revenue beat, exceptional cash generation (Q4 operating cash flow of ~$230M, free cash flow $207M), strong order momentum (BSI book-to-bill >1.0, ~7 months backlog), large multiyear BEST orders (> $500M), and constructive FY2026 guidance with targeted margin expansion and raised cost-savings expectations. However, these positives are offset by material near-term challenges: persistent organic revenue declines (Q4 -5.1%, FY -3.7%), significant margin compression (Q4 non-GAAP operating margin down 240 bps), pressure from tariffs and FX, weak U.S. academic/government funding, and expected Q1 2026 organic decline. Taken together, the call presents a credible operational and financial recovery plan built on strong cash flow and order momentum, but also substantial short-term headwinds and execution/timing risks.View all BRKR earnings summariesBRKR Stock 12 Month Forecast
Average Price Target
$47.92
▲(19.47% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---